13th week of 2016 patent applcation highlights part 6 |
Patent application number | Title | Published |
20160089290 | PATIENT TRANSFER SYSTEM - A patient transfer system includes a patient transfer assembly and a patient transfer device. The assembly includes a sheet of corrugatable material, at least one stiffener that resists corrugation of the sheet in a first dimension when the patient transfer assembly including the sheet corrugated in a second dimension is inserted between the patient and a surface of a first resting device on which the patient rests. The sheet includes portions at which pulling in a direction along the second dimension decorrugates the sheet between the patient and the surface and fasteners. The device includes a sheet engaging assembly that pulls at least one of the fasteners in a direction along the first dimension to slide the decorrugated sheet relative to the surface thereby transferring the patient. | 2016-03-31 |
20160089291 | METHODS OF TRANSFERRING PATIENTS - A method of transferring a patient from a first resting surface to a second resting surface includes inserting a corrugated sheet into a channel formed between the patient and the first resting surface, extending a portion of the sheet between the patient and the first resting surface to under the patient's feet, extending a portion of the sheet between the patient and the first resting surface to under the patient's head, and pulling laterally on the sheet to slide the sheet from the first resting surface to the second resting surface thereby transferring the patient. | 2016-03-31 |
20160089292 | DEVICE FOR SUPPORTING A PATIENT TO ALLOW PERFORMANCE OF A BREAST EXAM - A device for supporting a patient to allow an exam to be performed on the patient's breast, including a supporting table which has a longitudinal axis of extension and on which the patient can lie in a reclining position; the supporting table is provided, in proximity to one end of it, with a through hole for receiving the breast to be examined; a mounting frame for mounting the supporting table and equipped with at least one actuator for adjusting the supporting table in height; the supporting table is divided into a first portion and second portion along an axis; the first portion is smaller in extension along the longitudinal axis than the second portion and is provided with the through hole; the two portions are movably connected to each other. | 2016-03-31 |
20160089293 | Height Adjustable Pillow for Use in Surgery - A height-adjustable pillow for supporting a patient's head. The pillow includes a casing of flexible material defining a casing volume and a volume of filler material partially occupying in said casing volume. The casing volume is compressible and expandable. The casing volume includes a support portion positioned above a base portion. An air valve is associated with the casing for introducing air into and evacuating air from said casing volume. | 2016-03-31 |
20160089294 | DUAL-CHAIR ASSEMBLY - A dual-chair assembly is disclosed having a practitioner chair rotatably coupled to a base by an extension arm, the base fixedly attached to a ground surface, and disposed a separation distance from the practitioner chair. The dual-chair assembly also includes a subject chair coupled to and supported by the base. A practitioner control is communicatively coupled to practitioner chair actuators, the practitioner control including a user input interface operably configured for receiving a practitioner input, and, as a result of the practitioner input, causing the practitioner chair actuators to perform at least one of rotating the practitioner chair about the subject chair; adjusting an elevation of the practitioner chair; and rotating at least one of a roll angle, a pitch angle, and a yaw angle of the practitioner chair. | 2016-03-31 |
20160089295 | LEFT ARM TRANS ACCESS POSITIONING APPARATUS - In one example, an apparatus for positioning a patient's forearm during a medical procedure has a main panel portion, an extended panel portion and a base panel portion. The main panel portion has an inner surface and an outer surface, a first longitudinal side edge, a second longitudinal side edge, a first latitudinal side edge and a second latitudinal side edge. The extended panel portion has panel portion having a proximal end edge and a distal end edge, and an inner surface, wherein said distal end edge forms an angled configuration with said main panel portion for positioning the patient's left forearm and wrist suitably for receiving an arterial catheter. The base panel portion has a first longitudinal side edge and a second longitudinal side edge, wherein said first longitudinal side edge of said base panel portion extends generally perpendicularly outward from said second longitudinal side edge of said main panel portion. | 2016-03-31 |
20160089296 | APPARATUS FOR TREATING THE HUMAN OR ANIMAL BODY WITH MECHANICAL STROKES - The invention relates to an apparatus for treating a human or animal body by mechanical strokes, wherein an applicator for being placed on the patient's body surface has a basically oblique front area portion in an angle between 30° and 60° to the stroke direction. | 2016-03-31 |
20160089297 | APPARATUS FOR TREATING THE HUMAN OR ANIMAL BODY WITH MECHANICAL STROKES - The invention relates to an apparatus for treating the human or animal body by strokes and an applicator 11 provided for that purpose, having a curved-flat shape with a concave and a convex lateral face. | 2016-03-31 |
20160089298 | Device for Mitigating Motion Sickness and Other Responses to Inconsistent Sensory Information - Embodiments of the invention can mitigate motion sickness by disrupting, controlling, or influencing anatomy of the vestibular system, including, for example, otoliths, endolymph, and hair follicles. An embodiment of the invention may induce vibrations in the vestibular system, including otoliths and/or semicircular canals of the inner ear, thereby causing noisy or unreliable sensory information in signals sent to the brain from the vestibular system. Due to this noisy or unreliable sensory information, the brain, as part of a normal physiological response, may rely less on signals received from vestibular system and rely more heavily on other sources, thereby mitigating the motion sickness response, vertigo, vestibular migraines, and other physiological responses to inconsistent sensory information. Vibrations in the vestibular system may be induced by an agitator placed on an individual's head near the vestibular system. Vibrations in the vestibular system may also be induced by a transducer placed near the eardrum or directly on an individual's head. Embodiments of the invention may optionally include implantable components in addition to extracorporeal components. | 2016-03-31 |
20160089299 | EDEMA THERAPY APPARATUS - An edema therapy apparatus for the treatment and therapy of such conditions as edema, lymphedema, clotting and thrombosis. Apparatus is characterized by flexible wrap containing a plurality of vibration motors housed within a corresponding plurality of vibration motors mounts, all of which integrate into wrap. Vibration motors are inserted into vibration motor mounts allowing transfer of vibration from the motors themselves to the applied area. Vibration motors are connected by a wired circuit, which is coupled to a barrel plug adapter at an opposing end of the apparatus. Power is to be applied to the circuit containing the motors by a portable power supply housing a plurality of batteries to supply voltage. Function is control by way of an on-off switch located on the power supply. | 2016-03-31 |
20160089300 | TIMED SEQUENCE INDICATORS - A containment system for packaging a plurality of products that are to be accessed in a predetermined sequence. The containment system includes a plurality of product compartments that each holds at least one of the plurality of products. Indicators having a gas reactive material that changes appearance after a predetermined period of time of exposure to ambient air are deployed when gas cover seals are removed or broken to access a product in the product compartment. | 2016-03-31 |
20160089301 | SYSTEM AND METHOD FOR PERSONALIZED INJECTION TREATMENT - An automated system ( | 2016-03-31 |
20160089302 | DOSING STATION FOR A CAPSULE FILLING MACHINE - A dosing station for a capsule filling machine comprises a dosing unit in which capsule lower parts are filled with a filling material via a filling apparatus and a drive unit with at least one drive that drives at least one component of the dosing unit. The drive unit is arranged beneath a supporting plate, and detachable fastening and coupling means detachably fastens the dosing unit on the supporting plate. Where the dosing unit is detachably fastened on the supporting plate, the at least one drive is coupled to the at least one component. In the detached state of the dosing unit from the supporting plate, the coupling of the at least one drive to the at least one component is canceled. In this way, the dosing unit can be removed as a module from the dosing station. | 2016-03-31 |
20160089303 | MANAGING MEDICATIONS AT THE BEDSIDE - Modular automated dispensing systems for dispensing secured medications in a medical environment are provided. The system includes a compact enclosure configured to be disposed in a medical treatment area without taking up valuable floor space. The system includes lockable drawers having one or more compartments for storing and dispensing medications or medical supplies. The system is unlocked by use of an access control interface internally or externally connected directly to the system, or networked to the system through a medical center network. | 2016-03-31 |
20160089304 | MEDICATION DISPENSING SYSTEM - The present invention relates to a medication tray comprising a plurality a sealed vessels comprising one or more doses of a medicament; a plurality of individually spaced compartments that are adapted to receive the individually sealed vessels; and means for releasably retaining said sealed vessels within said compartments. The tray further comprises a detection means adapted to detect and monitor when individual vessel are dispensed from the compartments of the tray. | 2016-03-31 |
20160089305 | SYSTEM FOR SEALING A CONTAINER FOR STORING AND DELIVERING A PRODUCT - In an embodiment, a system including a closure device, the closure device including an opening for providing fluid communication there through, an outflow component configured to be disposed over the closure device, the outflow component including an outflow aperture to provide fluid communication between the outflow component and a user, and a securing member for supporting the outflow component in a position over the closure device is provided. The system further includes a stopper component removably engageable with the opening of the closure device, wherein when the stopper component is engaged with the opening, the stopper component obstructs the opening preventing a flow of fluid through the opening, and wherein displacement of the stopper component from the opening allows fluid communication through the opening. | 2016-03-31 |
20160089306 | STACKABLE BABY BOTTLE ASSEMBLY WITH NESTABLE CAP AND METHOD THEREFOR - A stackable baby bottle assembly with a nestable cap comprises a bottle base, a ring, a nipple, a cap, and, optionally, a sieve. The bottle base includes a plurality of edge members. A plurality of bottle bases may be stacked for storage. When a plurality of bottle bases are stacked, the edge members form space between the bottle bases, thereby permitting air to flow between the bottle bases. The bottle base and cap may include nesting regions, such that the cap may be inverted and snapped onto place onto the bottom of the bottle base, which may be convenient during feeding. A plurality of caps may be stacked for storage. | 2016-03-31 |
20160089307 | AUXILIARY BOTTLE FEEDING APPARATUS AND BABY PRODUCT TO WHICH AUXILIARY BOTTLE FEEDING APPARATUS IS MOUNTED - The present invention relates to a baby product, and more particularly to an auxiliary bottle feeding apparatus and a baby product to which the auxiliary bottle feeding apparatus is mounted, which are conceived to perform bottle feeding even without assistance of a guardian while taking care of a baby, and serve as a means for making the face of a baby seated in a bottle feeding posture on the baby product and a pacifier of a baby bottle located on a space to face each other while being spaced apart from each other by a predetermined interval, and consistently fixing said state at the same time. | 2016-03-31 |
20160089308 | Targeted And Individualized Delivery Of Skincare Treatments With Micro-Current In A Mask Or Patch Form - Cosmetic facial treatment delivery sheets with both personalized skincare benefit agents and customized iontophoresis micro-current zones are provided for delivering skincare treatments to multiple targeted areas of the skin to treat different concerns of an individual user. The sheets are made by printing skin benefit agents on a dissolvable or non-dissolvable substrate and then printing micro-current generators with power sources in different locations on the substrate. The micro-current generators facilitate delivery of the benefit agents by iontophoresis, or directly affect treatment by delivery of micro-current to the skin. | 2016-03-31 |
20160089309 | TARGETED AND INDIVIDUALIZED DELIVERY OF SKINCARE TREATMENTS WITH MICROCURRENT IN A MASK OR PATCH FORM - Cosmetic facial treatment delivery sheets with both personalized skincare benefit agents and customized iontophoresis micro-current zones are provided for delivering skincare treatments to multiple targeted areas of the skin to treat different concerns of an individual user. The sheets are made by printing skin benefit agents on a dissolvable or non-dissolvable first substrate and then printing micro-current generators with power sources in different locations on a second substrate. The first substrate and second substrate are assembled to form the delivery sheets. The micro-current generators facilitate delivery of the benefit agents by iontophoresis, or directly affect treatment by delivery of micro-current to the skin. | 2016-03-31 |
20160089310 | TOPICAL COMPOSITIONS - The present invention relates to a topical composition comprising at least one ingredient selected from the group consisting of a sebum control agent, a skin exfoliation agent and/or a collagen enhancing agent and a porous cross-linked polymethylmethacrylate bead having a particle size D | 2016-03-31 |
20160089311 | HIGH UV PROTECTION ALCOHOL-FREE EMULSION SYSTEM, THAT IS CLEAR ON APPLICATION - The present invention relates to a sunscreen composition comprising:
| 2016-03-31 |
20160089312 | COSMETIC COMPOSITION CONTAINING AN OILY PHASE COMPRISING A SILICONE ELASTOMER IN DISPERSED AQUEOUS DROPLETS AND A PARTICULAR SURFACTANT - The invention relates to a cosmetic composition comprising at least an oily phase, the said oily phase comprising at least: (i) a silicone elastomer present in aqueous droplets which are dispersed in said oily phase, (ii) at least one particular surfactant chosen from: —a) silicone surfactants having a chemical structure comprising silicone side chains and hydrophilic side chains, of which the general formula (I) is: (I) —b) silicone surfactants having a chemical structure comprising hydrophilic chains at both ends (α- | 2016-03-31 |
20160089313 | Method for Searching for Malodor Control Agent, Malodor Control Agent, and Malodor Control Method - Provided are a method for searching for a malodor inhibitor by using the response of an olfactory receptor as an indicator; a method for inhibiting malodor based on the antagonism of olfactory receptors; and a malodor inhibitor. Disclosed are a method for searching for a malodor inhibitor, the method including: adding a test substance and a malodor-causing substance to any one olfactory receptor selected from the group consisting of OR51E1, OR2W1, OR10A6, OR51I2, and OR51L1, measuring the response of the olfactory receptor to the malodor-causing substance, identifying the test substance that suppresses the response of the olfactory receptor on the basis of the measured response, and selecting the identified test substance as a malodor inhibitor; an antagonist to any one olfactory receptor selected from the group consisting of OR51E1, OR2W1, OR10A6, OR51I2, and OR51L1; a method for inhibiting malodor using the antagonist. | 2016-03-31 |
20160089314 | STABLE LOTION EMULSION COMPOSITION AND WET WIPE - A lotion emulsion composition comprising a preservative enhancing agent and a rheology modifier, wherein the preservative enhancing agent comprises one of sorbitan caprylate, glyceryl caprylate/caprate, or a combination thereof, the rheology modifier comprises a hydrocolloid, the pH of the lotion emulsion composition is less than about 4.2, and the combined amount of preservative enhancing agent and rheology modifier is less than about 0.3% by weight of the total lotion emulsion composition. | 2016-03-31 |
20160089315 | COMPOSITIONS AND METHODS FOR REDUCING CUTANEOUS MICROBIOME MALODOR - A deodorant composition comprising arginine, bicarbonate, zinc and carbonate, preferably arginine bicarbonate and zinc carbonate (ABZC), and one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras—generally to reduce axillary odor, promote the growth of | 2016-03-31 |
20160089316 | Compound, Composition, Polymer, Mylar Film and Method for Indicating Maximum Exposure to the Sun and UV Radiation - A composition for protecting from ultraviolet radiation is disclosed. The composition comprises a filter and an effectiveness indicator responsive to the reduction of effectiveness protection. | 2016-03-31 |
20160089317 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS - The present invention relates to antiperspirant and deodorant compositions comprising malodor reduction compositions and methods of making and using such antiperspirant and deodorant compositions. Such antiperspirant and deodorant compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent and when perfume is used to scent such compositions, such scent is not unduely altered by the malodor control technology. | 2016-03-31 |
20160089318 | PERSONAL CARE COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS - The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent and when perfume is used to scent such compositions, such scent is not unduly altered by the malodor control technology. | 2016-03-31 |
20160089319 | ACTIVES FOR STIMULATING DIFFERENTIATION OF KERATINOCYTES TO LIGHTEN HYPERPIGMENTED SKIN - A method is provided for identifying a material having an efficacy for reducing color contrast between a hyperpigmented skin lesion and skin surrounding the hyperpigmented skin lesion without directly affecting melanocytes or melanogenesis. The method includes the steps of applying a composition containing a material to be tested to the hyperpigmented skin lesion; and after an interval of time, observing whether the composition has effected at least one of inhibiting proliferation of keratinocytes, stimulating differentiation of keratinocytes, and improving compressive deformation of dermal papillae, in a basal layer of epidermis in the hyperpigmented lesion of skin. | 2016-03-31 |
20160089320 | Non-Synthetic Emulsion-Based Lipid Formulations and Methods of Use | 2016-03-31 |
20160089321 | ANTIPERSPIRANT COMPOSITIONS - The present invention provides an antiperspirant composition comprising at least 3.5% by weight of zinc phenolsulphonate or zinc lactate, wherein said composition is substantially free of aluminum salts. | 2016-03-31 |
20160089322 | Cleansing Compositions - The present invention relates to cleansing compositions including: (a) from about 3% to about 20% by weight based on the total weight of the composition amphoteric surfactant; and (b) an alkyl glucoside surfactant, wherein a ratio of alkyl glucoside surfactant to amphoteric surfactant is at least 1 to 1, the composition is free of ethoxylated surfactants, and the composition has a viscosity of at least 1000 centipoise. | 2016-03-31 |
20160089323 | METHODS FOR SMOOTHING WRINKLES AND SKIN TEXTURE IMPERFECTIONS - A skin smoothing composition that has from about 0.5 to about 10%, by weight, of an interpenetrating polymer that is a co-polymer of polyurethane and a polyacrylic polymer. The composition further contains from about 0.1% to about 5%, by weight, of a thickener made from homopolymers of acrylic acid crosslinked with a cross linker selected from the group consisting of an allyl ether pentaerythritol, allyl ether of sucrose, allyl ether of propylene and mixtures thereof. And from about 10 to 98% water. | 2016-03-31 |
20160089324 | METHODS FOR SMOOTHING WRINKLES AND SKIN TEXTURE IMPERFECTIONS - A method for improving the condition of skin by following the steps of applying a first composition that has from about 0.5 to about 10%, by weight, of an interpenetrating polymer that is a co-polymer of polyurethane and a polyacrylic polymer. The first composition further contains from about 0.1% to about 5%, by weight, of a thickener made from homopolymers of acrylic acid crosslinked with a cross linker selected from the group consisting of an allyl ether pentaerythritol, allyl ether of sucrose, allyl ether of propylene and mixtures thereof, and from about 10 to 98% water. The next step is applying a second composition that is in a form of an aqueous solution, an organic solvent solution, an oil based solution, an emulsion, a suspension, an aqueous gel, an oil-in-water emulsion, a water-in-oil emulsion, a thickened aqueous gel, a thickened oil phase, an encapsulated oil phase, a solid oil phase, an aqueous solution comprising a plasticizer, and mixtures thereof. | 2016-03-31 |
20160089325 | SOAP COMPOSITION - A soap composition for the treatment of skin conditions and irritations, including 40-50 wt % soy oil, 15-25 wt % coconut oil, 1-10 wt % olive oil, 0.5-5 wt % cocoa butter, 15-25 wt % water, and 5-15 wt % sodium hydroxide. A lotion composition, including 85-99 wt % lotion base, 2-10% neem oil, and 0.5-5% black seed oil. A lip balm composition, including 80-99.999 wt % lip balm base, and 0.001-20 wt % of a composition of castor oil, palm kernel oil, aloe extract, carnauba wax, candelilla wax, cocoa butter, vanilla oil, vanilla, and combinations thereof. A method of treating a skin irritation by applying the soap composition to skin, and relieving the irritation. A method of making a soap composition. A method of treating a skin irritation by applying the lotion composition to skin, and relieving the irritation. | 2016-03-31 |
20160089326 | Composition for deodorizing breath and beverage made therefrom - A composition comprising an odor-suppressing mixture including parsley, alfalfa, oregano, and wheatgrass that cures halitosis. The odor-suppressing mixture comprises at least 50 weight percent of the composition. The composition is devoid of artificial preservatives, alcohol, sodium, sucrose and artificial sugar substitutes, and the odor-suppressing mixture may include the additional ingredients mint, spearmint, or thyme. A beverage is made from this composition. | 2016-03-31 |
20160089327 | Method of Improving Aging Appearance of Skin by Modulation of WIPI-1 - Methods of using WIPI-1 to impart anti-aging benefits to the skin and/or improve skin conditions resulting from reduced autophagy activity. | 2016-03-31 |
20160089328 | SUBLINGUAL APOMORPHINE - The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith. | 2016-03-31 |
20160089329 | EXTENDED RELEASE OF NEUREGULIN FOR TREATING HEART FAILURE - The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump. | 2016-03-31 |
20160089330 | DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS - Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided. | 2016-03-31 |
20160089331 | Method and Kit for Bowel Preparation - The present invention provides methods and taste-modifying kits for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods and taste-modifying kits can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty. | 2016-03-31 |
20160089332 | GEL-LIKE COMPOSITION HAVING HIGH UBIQUINOL CONTENT - This invention relates to a gel-like composition in which ubiquinol is dispersed and stabilized in a gel and which contains 0.2 to 5% by weight of ubiquinol, 5 to 15% by weight of gelatin, 55 to 80% by weight of carbohydrate and/or water-soluble dietary fiber, and 9 to 18% by weight of water, and further contains ascorbic acid and/or gallate type catechin. | 2016-03-31 |
20160089333 | [0001] FOAM-FORMING COMPOSITIONS AND METHODS FOR DELIVERING AN ACTIVE TO A BODY CAVITY - Provided is a foam-forming formulation and method of treating an infection in a body cavity. The foam-forming formulation contains hydrogen peroxide, monoglyceride crystals, at least one acid and/or buffer which is present in an amount to provide a pH of 3 to 5 within a body cavity, a blowing agent in an amount to blow the foam-forming composition and form a foam, and water. The foam-forming composition is suitable application to body cavity when blown to form the foam and the form degrades at a body temperature to release the hydrogen peroxide to tissues in the body cavity at a pH of 3 to 5. Also provided is a foam-forming composition vehicle for delivering an active agent. | 2016-03-31 |
20160089334 | POROUS METAL OXIDE PARTICLES, PRODUCTION METHOD THEREOF AND APPLICATION THEREOF - Provided are porous metal oxide particles, in which 50% mean particle size by volume is equal to or larger than 50 nm and equal to or smaller than 300 nm, ratio of 90% mean particle size by volume to 50% mean particle size by volume (D90/D50) is equal to or lower than 2.0, the particles have mesopores having a pore size determined by BJH method of equal to or larger than 5 nm and equal to or smaller than 30 nm, and the structure of the pores is a three-dimensional cubic phase structure. | 2016-03-31 |
20160089335 | DRUG LOADED MICROSPHERES FOR POST-OPERATIVE CHRONIC PAIN - A microsphere is disclosed. The microsphere includes at least one biodegradable polymer and at least one local anesthetic, wherein about 75% of the at least one local anesthetic is released by about 72 hours and from about 80% to about 90% of the at least one local anesthetic is released by about 120 hours, thereby relieving chronic pain for at least 28 days. | 2016-03-31 |
20160089336 | Octreotide depot formulation with constantly high exposure levels - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs). | 2016-03-31 |
20160089337 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 2016-03-31 |
20160089338 | ORALLY DISINTEGRABLE TABLET - Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. | 2016-03-31 |
20160089339 | CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE - Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: ( | 2016-03-31 |
20160089340 | COMPOSITION COMPRISING FARNESOL AND USE THEREOF - A method of increasing PGC-1α gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions. | 2016-03-31 |
20160089341 | METHODS FOR TREATING AND PREVENTING STATUS EPILEPTICUS AND ORGANOPHOSPHATE POISONING - Disclosed are compounds, compositions and methods for stopping seizures, including status epilepticus, and are useful for the treatment and prevention of seizure disorders. | 2016-03-31 |
20160089342 | METHOD OF INHIBITING XANTHINE OXIDASE ACTIVITY IN A CELL - Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia. | 2016-03-31 |
20160089343 | MICROSIZED CURCUMIN COMPOSITIONS - Disclosed herein are formulations for the local delivery of therapeutically effective doses of curcumin that provide sufficient serum levels of curcumin to treat diseases such as head and neck disorders and upper aerodigestive disorders. | 2016-03-31 |
20160089344 | NANOPARTICLE TARGETED DRUG DELIVERY TO THE LUNGS USING EXTRA-TESTICULAR SERTOLI CELLS - A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection. | 2016-03-31 |
20160089345 | KIT OF OPHTHALMIC COMPOSITION - An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little. | 2016-03-31 |
20160089346 | METHOD OF TREATMENT FOR BODY CONTOURING - Provided herein are methods involving body contouring applications including treatments to reduce subcutaneous fat. The methods include the determination of patient suitability for body contouring treatment by evaluating one or more patient assessments. In various implementations, a patient determined to be suitable for body contouring treatment is administered a composition comprising a beta-2 adrenergic receptor agonist to the region of the body comprising subcutaneous fat, such as the central abdominal or submental region. | 2016-03-31 |
20160089347 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATION OF NEUROTRANSMITTERS - This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain. | 2016-03-31 |
20160089348 | USE OF AN S1P RECEPTOR AGONIST - The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy. | 2016-03-31 |
20160089349 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS - The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome. | 2016-03-31 |
20160089350 | Enzyme Conjugate and Prodrug Cancer Therapy - A method and composition for treating a cancerous tumor in a subject by targeting the tumor's vasculature using an enzyme conjugate comprising a ligand which binds to endothelial cells in the tumor vasculature and converts a prodrug administered to the subject into an anticancer drug in the tumor vasculature. | 2016-03-31 |
20160089351 | USE OF DENCICHINE IN PREPARATION OF DRUG FOR TREATING THROMBOCYTOPENIA - Disclosed are uses of drugs for treating thrombocytopenia, in particular the use of dencichine in preparation of drugs for treating thrombocytopenia. By adding pharmaceutically acceptable conventional adjuvant material, dencichine can be prepared into an oral preparation or an injection. A pharmacodynamic trial shows that the dencichine can effectively inhibit the thrombocytopenia caused by chemotherapy drugs, and treat thrombocytopenic purpura with obvious curative effect and low toxic side effects. | 2016-03-31 |
20160089352 | CELL MEMBRANE TRANSPORT PROMOTER FOR SELECTIVE 5-HT1A SEROTONIN RECEPTORS - Provided is a cellular membrane trafficking promoter for a 5-HT | 2016-03-31 |
20160089353 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 2016-03-31 |
20160089354 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Cancer Cell Growth - Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia. | 2016-03-31 |
20160089355 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. | 2016-03-31 |
20160089356 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF - This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder such as muscular dystrophies including Duchenne muscular dystrophy and Becker muscular dystrophy. | 2016-03-31 |
20160089357 | USE OF FRACTIONATED PRODUCTS OF GAMBOGE RESIN IN THE TREATMENT OF CANCER, PAIN, AND INFLAMMATION - Disclosed herein are seventeen new compounds and five fractionated products obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds and the five fractionated products have activities in inhibiting the growth of tumor/cancer cells. In addition, the acetone-extracted product of gamboge resin and the five fractionated products obtained therefrom have analgesic and anti-inflammatory effects. | 2016-03-31 |
20160089358 | COMPOSITION COMPRISING A COMPLEX OF (+)-CATECHIN AND AMINO ACID FOR THE TREATMENT AND PREVENTION OF CANCER - The invention relates to a gastroenteric therapeutic composition for oral administration, comprising a compound of monomeric (+)-catechin and at least one basic amino acid, said composition being characterized in that it is used in the form of a complex of (+)-catechin and at least one basic amino acid or at least one derivative or precursor of a basic amino acid for the curative and/or preventive treatment of cancer, said complex having a molar equivalence ratio of the monomeric (+)-catechin to the at least one basic amino acid or the at least one basic amino acid derivative of between 1:1 and 1:2.5. | 2016-03-31 |
20160089359 | COMPOSITION FOR PREVENTING OR TREATING CLIMACTERIC SYMPTOMS COMPRISING SOYBEAN EXTRACT COMPRISING COUMESTROL AS AN ACTIVE INGREDIENT - The present invention relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a soybean extract comprising coumestrol as an active ingredient, and more specifically relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a germinated and fermented soybean extract comprising coumestrol as an active ingredient. | 2016-03-31 |
20160089360 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES - The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein. | 2016-03-31 |
20160089361 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA - The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6. | 2016-03-31 |
20160089362 | Method for Topically Treating Actinic Keratosis on the Trunk (except chest) or Extremities with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate) - The invention relates to the treatment of actinic keratosis on the trunk (except chest) or Extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). | 2016-03-31 |
20160089363 | COMPOSITIONS AND METHODS FOR TREATING MICROBIOTA-RELATED PSYCHOTROPIC CONDITIONS AND DISEASES - In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor, for example, where the microbial or bacterial flora of the bowel manufactures neurotoxins or neurotoxic agents that enter the body through the gastrointestinal (GI) tract, e.g. the colon, and reach the systemic space, e.g., by neural streaming or via the circulation, to reach the central nervous system (CNS), including the brain, the peripheral nervous system (PNS), and other nervous systems. In alternative embodiments, methods and compositions of the invention comprise or comprise use of medications, formulations and pharmaceuticals comprising rifaximin or equivalent active agents that can suppress or eradicate the microbiota super-infection that causes various psychotropic disorders. These compositions have been found to be affective in a broad spectrum of disorders but particularly in the obsessive compulsive disorder group (OCD). | 2016-03-31 |
20160089364 | PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION - The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse. | 2016-03-31 |
20160089365 | IMMUNOSTIMULATORY COMPOUND - An immunostimulatory compound is disclosed. | 2016-03-31 |
20160089366 | BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS - Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer. | 2016-03-31 |
20160089367 | SUBLINGUAL APOMORPHINE - The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith. | 2016-03-31 |
20160089368 | TREATMENT OF MASTOCYTOSIS WITH MASITINIB - The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen. | 2016-03-31 |
20160089369 | AQUEOUS SUSPENSIONS OF TMC278 - This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection. | 2016-03-31 |
20160089370 | TREATMENT OR PREVENTION OF AUTISM DISORDERS USING MENTHOL, LINALOOL AND/OR ICILIN - Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of autism disorders are also provided, and the methods include administering such compositions. | 2016-03-31 |
20160089371 | Combination of Kinase Inhibitors and Uses Thereof - The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. | 2016-03-31 |
20160089372 | Compositions Useful for Treating Herpes Simplex Labialis and/or Herpes Esophagitis, and Methods Using Same - The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex labialis or herpes esophagitis, in a subject. In certain embodiments, the compositions of the invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent. | 2016-03-31 |
20160089373 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY - The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk. | 2016-03-31 |
20160089374 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE - Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL). | 2016-03-31 |
20160089375 | TOPICAL OCULAR ANALGESIC AGENTS - The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed. | 2016-03-31 |
20160089376 | MODULATION OF REACTIVATION OF A LATENT VIRUS - The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent. | 2016-03-31 |
20160089377 | THERAPEUTIC TARGETING OF THE MTOR PATHWAY IN NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISEASE - The present invention relates to methods of treating various neurodevelopmental and neuropsychiatric diseases which employ inhibition of the mTOR pathway, particularly using mTOR kinase inhibitors. It is based, at least in part, on extensive phenotypic characterization of a knock-out mouse model of Caspr2, the murine ortholog of CNTNAP2, which indicate that the mechanism via which CNTNAP2 deficits lead to neuropsychiatric disorders is overactivation of the mTOR pathway. Accordingly, the present invention provides for methods of treating subjects suffering from neurodevelopmental and/or neuropsychiatric disorders comprising administering, to the subject, an agent that inhibits the mTOR pathway. In particular non-limiting embodiments, the inhibitor of the mTOR pathway is a mTOR kinase inhibitor such as, but not limited to, WYE125132 and analogous compounds. In a non-limiting subset of embodiments, subjects may be tested to determine whether they have a copy number variation or mutation in CNTNAP2 and where such a copy number variation or mutation is present treatment with a mTOR pathway inhibitor may be initiated. | 2016-03-31 |
20160089378 | TREATMENT OF OSTEOARTHRITIS PAIN - This invention discloses a method of treatment of osteoarthritis pain by administration of a histamine H | 2016-03-31 |
20160089379 | TREATMENT OF NEUROLOGICAL AND OTHER DISORDERS - Methods and implants for treating neurological, muscular and other cells having an electrical potential, with an infusion of antagonists or inverse agonists (such as flumazenil for the benzodiazepine receptor, or naltrexone for the opiate receptor or other antagonist for other receptor) at rates that are so low that only a small percentage of receptors have the antagonist effect at any one time. | 2016-03-31 |
20160089380 | PROGESTERONE IMPREGNATED VAGINAL RING/PESSARY - A progesterone impregnated vaginal ring/pessary includes a circumferential outer ring composed of a progesterone impregnated biomaterial, wherein the outer ring has a substantially circular configuration while lying flat with an outer diameter of 60 mm to 70 mm and a thickness of approximately 5 mm. The vaginal ring/pessary also includes a transparent membrane extending along an interior space defined by the outer ring. The transparent membrane is composed of a silicone polymer, has a thickness of 1 mm to 3 mm, and includes a plurality of apertures, which are 4 mm to 5 mm in diameter, circumferentially spaced about a perimeter of the transparent membrane. | 2016-03-31 |
20160089381 | STABILITY OF PROGESTOGEN FORMULATIONS - In a preparation for hormone replacement therapy having a low content of progestogen, the stability of the progestogen component can be enhanced by using a cellulosic binder, for example hydroxypropylcellulose, in stead of a non-cellulosic binder. | 2016-03-31 |
20160089382 | STEROIDAL NITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA, ALZHEIMER AND PARKINSON DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS - The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis. | 2016-03-31 |
20160089383 | NUTRITIONAL SUPPLEMENTS - Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements. | 2016-03-31 |
20160089384 | VITAMIN D-CONTAINING NUTRITIONAL SUPPLEMENTS - Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements. | 2016-03-31 |
20160089385 | VITAMIN D RECEPTOR AGONISTS TO TREAT DISEASES INVOLVING CXCL12 ACTIVITY - Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes. | 2016-03-31 |
20160089386 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS - Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent. | 2016-03-31 |
20160089387 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS - Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent. | 2016-03-31 |
20160089388 | CYTOTOXIC AGENTS FOR THE TREATMENT OF CANCER - The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolvtically or enzymaticaily in the body of the patient in a pH-dependent manner. | 2016-03-31 |
20160089389 | CHEMOEMBOLISATION - A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin. | 2016-03-31 |